The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis
Open accessAbstract
BACKGROUND: Pretreatment drug resistance in people initiating or re-initiating antiretroviral therapy (ART) containing non-nucleoside reverse transcriptase inhibitors (NNRTIs) might compromise HIV control in low-income and middle-income countries (LMICs). We aimed to assess the scale of this problem and whether it is associated with the intiation or re-initiation of ART in people who have had previous exposure to antiretroviral drugs. METHODS: This study was a systematic review and meta-regression analysis. We assessed regional prevalence of pretreatment drug resistance and risk of pretreatment drug resistance in people initiating ART who reported previous ART exposure. We systematically screened publications and unpublished datasets for pretreatment drug-resistance data in individuals in LMICs initiating or re-initiating first-line ART from LMICs. We searched for studies in PubMed and Embase and conference abstracts and presentations from the Conference on Retroviruses and Opportunistic Infections, the International AIDS Society Conference, and the International Drug Resistance Workshop for the period Jan 1, 2001, to Dec 31, 2016. To assess the prevalence of drug resistance within a specified region at any specific timepoint, we extracted study level data and pooled prevalence estimates within the region using an empty logistic regression model with a random effect at the study level. We used random effects meta-regression to relate sampling year to prevalence of pretreatment drug resistance within geographical regions. FINDINGS: We identified 358 datasets that contributed data to our analyses, representing 56 044 adults in 63 countries. Prevalence estimates of pretreatment NNRTI resistance in 2016 were 11·0% (7·5-15·9) in southern Africa, 10·1% (5·1-19·4) in eastern Africa, 7·2% (2·9-16·5) in western and central Africa, and 9·4% (6·6-13·2) in Latin America and the Caribbean. There were substantial increases in pretreatment NNRTI resistance per year in all regions. The yearly increases in the odds of pretreatment drug resistance were 23% (95% CI 16-29) in southern Africa, 17% (5-30) in eastern Africa, 17% (6-29) in western and central Africa, 11% (5-18) in Latin America and the Caribbean, and 11% (2-20) in Asia. Estimated increases in the absolute prevalence of pretreatment drug resistance between 2015 and 2016 ranged from 0·3% in Asia to 1·8% in southern Africa. INTERPRETATION: Pretreatment drug resistance is increasing at substantial rate in LMICs, especially in sub-Saharan Africa. In 2016, the prevalence of pretreatment NNRTI resistance was near WHO's 10% threshold for changing first-line ART in southern and eastern Africa and Latin America, underscoring the need for routine national HIV drug-resistance surveillance and review of national policies for first-line ART regimen composition. FUNDING: Bill & Melinda Gates Foundation and World Health Organization.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update
Bennett, D. E., Camacho, R. J., Otelea, D., Kuritzkes, D. R., Fleury, H., Kiuchi, M., Heneine, W., Kantor, R., Jordan, M. R., Schapiro, J. M., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004724 · Cited by 938
Self-citationGupta, R. K., Jordan, M. R., Sultan, B. J., Hill, A., Davis, D. H., Gregson, J., Sawyer, A. W., Hamers, R. L., Ndembi, N., Pillay, D., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61038-1 · Cited by 364
Self-citationGregson, J., Tang, M., Ndembi, N., Hamers, R. L., Rhee, S.-Y., Marconi, V. C., Diero, L., Brooks, K. A., Theys, K., Rinke de Wit, T., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)00536-8 · Cited by 267
Self-citationGupta, R. K., Hill, A., Sawyer, A. W., Cozzi-Lepri, A., von Wyl, V., Yerly, S., Lima, V. D., Günthard, H. F., Gilks, C., & Pillay, D. (2009) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(09)70136-7 · Cited by 254
Self-citationRhee, S.-Y., Blanco, J. L., Jordan, M. R., Taylor, J., Lemey, P., Varghese, V., Hamers, R. L., Bertagnolio, S., de Wit, T. F. R., Aghokeng, A. F., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001810 · Cited by 223
Self-citationHamers, R. L., Schuurman, R., Sigaloff, K. C., Wallis, C. L., Kityo, C., Siwale, M., Mandaliya, K., Ive, P., Botes, M. E., Wellington, M., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70255-9 · Cited by 190
Self-citationYap, S.-H., Sheen, C.-W., Fahey, J., Zanin, M., Tyssen, D., Lima, V. D., Wynhoven, B., Kuiper, M., Sluis-Cremer, N., Harrigan, P. R., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040335 · Cited by 162
Boender, T. S., Sigaloff, K., McMahon, J. H., Kiertiburanakul, S., Jordan, M. R., Barcarolo, J., Ford, N. P., de Wit, T. F. R., & Bertagnolio, S. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/civ556 · Cited by 161
Self-citationRhee, S., Jordan, M. R., Raizes, E. G., Chua, A., Parkin, N. T., Kantor, R., van Zyl, G. U., Mukui, I., Hosseinipour, M. C., Frenkel, L. M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0145772 · Cited by 99
Self-citationBoender, T. S., Kityo, C. M., Boerma, R. S., Hamers, R. L., Ondoa, P., Wellington, M., Siwale, M., Nankya, I., Kaudha, E., Akanmu, S. A., et al. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw218 · Cited by 99
Self-citation
Cited by
Massively multiplexed nucleic acid detection with Cas13
Ackerman, C. M., Myhrvold, C., Thakku, S. G., Freije, C. A., Metsky, H. C., Yang, D. K., Ye, S. H., Boehm, C. K., Kosoko-Thoroddsen, T.-S. F., Kehe, J., et al. (2020) · Nature · doi:10.1038/s41586-020-2279-8 · Cited by 803
Dolutegravir-Based or Low-Dose Efavirenz–Based Regimen for the Treatment of HIV-1
The NAMSAL ANRS 12313 Study Group (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1904340 · Cited by 326
Mo, Y., Oonsivilai, M., Lim, C., Niehus, R., & Cooper, B. S. (2023) · PLOS Medicine · doi:10.1371/journal.pmed.1004013 · Cited by 52
“Examples of pathogens that may become resistant during treatment include Mycobacterium tuberculosis, fluoroquinolone-resistant Enterobacterales, and human immunodeficiency virus, especially with inappropriate dosing and duration [11,12].”
BackgroundZhu, L., Huang, B., Wang, X., Ni, F., Ao, M., Wang, R., Zheng, B., Chen, C., Xue, J., Zhu, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51414-6 · Cited by 25
Mimtsoudis, I., Tsachouridou, O., Akinosoglou, K., & Metallidis, S. (2024) · Viruses · doi:10.3390/v16091392 · Cited by 13
Metadata
- Authors
- Gupta, R. K., Gregson, J., Parkin, N., Haile-Selassie, H., Tanuri, A., Andrade Forero, L., Kaleebu, P., Watera, C., Aghokeng, A., Mutenda, N., Dzangare, J., Hone, S., Hang, Z. Z., Garcia, J., Garcia, Z., Marchorro, P., Beteta, E., Giron, A., Hamers, R., Inzaule, S., Frenkel, L. M., Chung, M. H., de Oliveira, T., Pillay, D., Naidoo, K., Kharsany, A., Kugathasan, R., Cutino, T., Hunt, G., Avila Rios, S., Doherty, M., Jordan, M. R., & Bertagnolio, S.
- Venue
- The Lancet Infectious Diseases
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 18
- Issue
- 3
- Pages
- 346-355
- ISSN
- 1473-3099 (ISSN-L)
- OpenAlex
- W2773554166
- Cited by
- 414
- References
- 18
- FWCI
- 8.32
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. https://app.cochat.ai/papers/10.1016/s1473-3099(17)30702-8
- The paper
- Gupta, R. K., Gregson, J., Parkin, N., Haile-Selassie, H., Tanuri, A., Andrade Forero, L., Kaleebu, P., Watera, C., Aghokeng, A., Mutenda, N., Dzangare, J., Hone, S., Hang, Z. Z., Garcia, J., Garcia, Z., Marchorro, P., Beteta, E., Giron, A., Hamers, R., . . . Bertagnolio, S. (2018). HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(17)30702-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.